January 18, 2024
Lilly’s Donanemab Poised for FDA Decision amid Embraced Alzheimer’s Disease Competition
Alzheimer’s Disease, Donanemab, United States Food and Drug Administration, Lilly’s
Forta Healthcare: $55M Series A to Scale AI-Driven Parent-Led Autism Therapy and Expand Services
Forta, Child, Applied Behavior Analysis